TrialThe Lancet. Oncology2024

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Naval G Daver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.